Mark Shilkrut
Overview
Explore the profile of Mark Shilkrut including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yao J, Strosberg J, Fazio N, Pavel M, Bergsland E, Ruszniewski P, et al.
Endocr Relat Cancer
. 2021 Jan;
PMID: 33480358
Spartalizumab, a humanized anti-programmed death protein 1 (PD-1) monoclonal antibody, was evaluated in patients with well-differentiated metastatic grade 1/2 neuroendocrine tumors (NET) and poorly-differentiated gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC). In this...
2.
Long G, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al.
J Clin Oncol
. 2019 Apr;
37(15):1356-1358.
PMID: 30939092
No abstract available.
3.
Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al.
J Clin Oncol
. 2018 Oct;
36(35):3441-3449.
PMID: 30343620
Purpose: Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; < .001) in patients with resected V600-mutant stage III melanoma (BRF115532; COMBI-AD; ClinicalTrials.gov identifier: NCT01682083). We...
4.
Ma Q, Shilkrut M, Zhao Z, Li M, Batty N, Barber B
BMC Cancer
. 2018 Feb;
18(1):145.
PMID: 29409500
Background: Immunotherapies have advanced the treatment of metastatic melanoma; however, they are associated with immune-related toxicities. Patients with pre-existing autoimmune comorbidities are commonly excluded from clinical trials investigating immunotherapies in...
5.
Kaufman H, Andtbacka R, Collichio F, Wolf M, Zhao Z, Shilkrut M, et al.
J Immunother Cancer
. 2017 Sep;
5(1):72.
PMID: 28923101
Background: Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [complete or partial objective...
6.
Andtbacka R, Agarwala S, Ollila D, Hallmeyer S, Milhem M, Amatruda T, et al.
Head Neck
. 2016 Jul;
38(12):1752-1758.
PMID: 27407058
Background: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the...
7.
Andtbacka R, Ross M, Puzanov I, Milhem M, Collichio F, Delman K, et al.
Ann Surg Oncol
. 2016 Jun;
23(13):4169-4177.
PMID: 27342831
Purpose: Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy designed to induce tumor regression of injected lesions through direct lytic effects, and of uninjected lesions through induction of systemic antitumor immunity....
8.
Shilkrut M, Sapir E, Hanasoge S, Schipper M, Normolle D, Ben-Josef E, et al.
Am J Clin Oncol
. 2016 Feb;
41(4):326-331.
PMID: 26886946
Objectives: We have previously shown that refractory neuroendocrine tumors can respond to moderate doses of chemoradiotherapy. We completed a dose-escalation phase I/II trial combining hepatic arterial (HA) chemotherapy, chemoembolization, and...
9.
Ma Q, Zhao Z, Barber B, Shilkrut M
Adv Ther
. 2016 Jan;
33(2):282-9.
PMID: 26797898
Introduction: Isolated limb perfusion and infusion (ILP/ILI) are therapies for regional metastatic melanoma that allow high doses of anticancer drugs to be delivered directly into the circulation of an affected...
10.
Zhao S, Shilkrut M, Speers C, Liu M, Wilder-Romans K, Lawrence T, et al.
PLoS One
. 2015 May;
10(5):e0126631.
PMID: 25974184
Purpose: The molecular drivers of metastasis in breast cancer are not well understood. Therefore, we sought to identify the biological processes underlying distant progression and define a prognostic signature for...